Theialife Appoints New CEO

Ahead of phase 3 myopia push, late clinical-stage biopharmaceutical company takes on Thomas Ruggia as Chief Executive Officer

1

Theialife appointed Thomas Ruggia as CEO to advance its oral therapy for pediatric myopia into phase 3 development.
2

Ruggia has over 25 years of experience in ophthalmology and previously led global commercialization at Samsara Vision.
3

The company is preparing to initiate phase 3 trials of ND10, a first-in-class oral therapy targeting myopia progression in children.
4

ND10 is supported by over two decades of data from Denmark, showing encouraging efficacy and safety in over 1,200 treated children.
5

Theialife is also developing a broader ophthalmology pipeline, including treatments for dry eye disease and wet AMD.

1